Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer’s Disease Program

03-Jul-2012 - Poland

Selvita S.A. announced that its collaboration with Orion Corporationon SEL103 program, for the symptomatic treatment of Alzheimer’s disease has reached the main research milestone and that the jointly discovered molecules from two different chemical families will progress into further pre-clinical characterization before the selection of a candidate into development.

The companies entered into a global collaboration with the aim to discover, develop and commercialize SEL103, Selvita’s proprietary program for the treatment of Alzheimer’s disease and other cognitive disorders in 2010. Selvita is responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.

Under the terms of the agreement, Selvita is responsible for the discovery and Orion is responsible for the development and global commercialization.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances